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The World Health Organization estimates that 1 billion individuals suffer from vector-borne 
diseases (VBDs), accounting for 17% of all infectious diseases worldwide, and 1 million of these 
individuals die annually due to VBDs. In addition, recent reports highlight a disturbing picture 
regarding the current situation of VBDs in the continental Europe, UK, and China. These 
diseases are caused by pathogens transmitted by arthropod vectors such as ticks (e.g. Lyme 
disease caused by Borrelia burgdorferi, human granulocytic anaplasmosis caused by 
Anaplasma phagocytophilum, and tick-borne encephalitis (TBE) caused by TBE virus), 
mosquitoes (e.g. malaria caused by Plasmodium spp. and dengue fever caused by dengue 
virus), phlebotomine sand flies (e.g. various forms of human leishmaniasis caused by 
Leishmania spp.), tsetse flies (e.g. sleeping sickness caused by Trypanosoma brucei), and 
Triatomine bugs (e.g. Chagas disease caused by Trypanosoma cruzi). Effective vaccination 
strategies to control most of the VBDs have not been successfully developed or implemented, 
and the use of insecticides and/or chemotherapy has resulted in an increasing number of 
insecticide-resistant vectors and drug-resistant pathogens. Therefore, alternative strategies for 
control of VBDs are urgently needed. During evolution, hominid primates and humans lost the 
gene encoding the enzyme to synthesize the carbohydrate Galactose-alpha-1,3-galactose (α-
Gal) that resulted in an almost unique capacity to produce high antibody titers against α-Gal. 
This process may be viewed as a major evolutionary adaptation for protection against VBDs. 
Other mammals do not produce anti-α-Gal antibodies because they express α-Gal, which is 
recognized as a self-antigen resulting in tolerogenic immune responses. Carbohydrate-based 
vaccines have shown promising results against various infectious pathogens such as Neisseria 
meningitidis, Haemophilus influenzae type b, and Salmonella typhi. Recently, Yilmaz et al. 
found that bacteria expressing α-Gal in the gut microbiota of mice with knockout α-Gal 
pathway trigger a systemic antibody response that protects against transmission of malaria-
causing Plasmodium parasites by Anopheles mosquitoes. The sterile protection against malaria 
transmission is achieved by α-Gal-specific IgM and IgG antibodies that neutralize Plasmodium 
sporozoites via a mechanism involving the binding of these immunoglobulins to the α-Gal 
moieties on the surface of the parasite that activates the classical complement pathway. This 
was a groundbreaking finding that may greatly impact the control of human VBDs. Notably, 
when α-Gal is used for immunization, IgM and IgG responses are also induced and have a 
protective role. In sharp contrast to these findings, anti-α-Gal IgE response induced by tick 
bites has been associated with anaphylactic reactions with still unknown implications for 
susceptibility to tick-borne pathogens. These results suggest that the immune response to α-
Gal may be highly influenced by the context in which this antigen is presented to the immune 
system. In addition to Plasmodium, trypanosomatid protozoan parasites such as Trypanosoma 
spp. and Leishmania spp. are probably vector-borne pathogens that also contain α-Gal on their 
surface, suggesting that the protective effect of anti-α-Gal immune response may extend to a 
larger number of pathogens. However, the challenge is to implement effective and easy-to-
deliver prevention therapies using α-Gal. One possible strategy is the use of probiotics (defined 
as ‘live microorganisms that, when administered in adequate amounts, confer a health benefit 
to the host’) containing α-Gal-producing bacteria such as Lactobacillus spp. as dietary 
supplements. This approach has the advantage that, in general, probiotic-based products are 
safe, easy to distribute, well received by the public, and with a well-established regulatory 
body. In addition, probiotic-based vaccines may have short-term and long-term beneficial 
effects to mucosal and systemic immunity. In fact, probiotics were proposed as an alternative 
to antibiotics and show antimicrobial effects that have been used to control infectious and 
parasitic agents such as Candida spp., Helicobacter pylori, Clostridium difficile, and Toxocara 
spp. 
The antimicrobial mechanisms of action of probiotics are diverse and include immunologic and 
non-immunologic responses, and also direct effects on the pathogens. A dilemma posed to 
probiotic-based vaccines is that some species of microbes have beneficial, but also pathogenic 
strains, and therefore, the use of the beneficial strains will raise safety concerns. For instance, 
Enterococcus faecalis strain CECT 7121 has a direct larvicide effect on T. canis larvae but 
regulatory bodies may not accept a probiotic comprising E. faecalis because many pathogenic 
strains are known for this bacterium. Likewise, the protective role of α-Gal against malaria was 
related to an Escherichia coli strain for which pathogenic strains also exist. Nevertheless, 
probiotics include several microorganisms, mostly within Lactobacillus or Bifidobacterium 
genera. Interestingly, gut colonization by the human gut pathobiont E. coli O86:B7, but not by 
the probiotic L. casei, induce an increase in the levels of anti-α-Gal-specific IgG and IgM. 
Apparently, both E. coli O86:B7 and L. casei contain α-Gal on their surfaces. In addition, Dahl et 
al. showed that even when the α-Gal epitope is highly represented in different enterobacteria 
of the gut microbiota of α-Gal knockout mice, no response to this antigen was induced without 
previous immunization. This raises the question whether all probiotic bacteria expressing α-Gal 
are able to induce a protective anti- α-Gal antibody response. Importantly, the expression of α-
Gal by members of the family Enterobacteriaceae (Gram-negative bacteria, e.g. E. coli spp.) is 
mainly associated with the bacterial capsule and cell wall glycoproteins, as well as with 
carbohydrate units of bacterial lipopolysaccharide (LPS). However, Lactobacillus spp. are Gram-
positive bacteria and do not produce LPS. Likewise, other E. coli spp. such as E. coli K2 strain 
may not produce α-Gal. The association of α-Gal to highly immunogenic components such as 
LPS in the membrane of pathogenic bacteria like E. coli O86:B7 may have a major impact in the 
immune response elicited against this antigen. To overcome this difficulty, beneficial probiotic 
species expressing α-Gal may be combined with adjuvants such as toll-like receptors (TLRs). 
TLRs are pattern recognition receptors expressed by various cells of the gastrointestinal track, 
including epithelial and immune cells. Differential activation of TLRs by microbiota or invading 
pathogens may contribute to intestinal homeostasis or to the initiation of inflammatory 
responses, respectively. It is well known that LPS is a specific activator of TLR4. TLR4 agonists 
such as LPS induce the activation of the nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-kB) signaling, which elicit a pro-inflammatory cytokine production. TLR4 activation 
is also associated to increased intestinal permeability and enhanced bacterial translocation to 
inner lamina. In contrast, activation of TLR9 by unmethylated CpG motifs in intestinal epithelial 
cells suppresses NF-kB-induced proinflammatory cytokine production and contributes to 
intestinal homeostasis. Lactobacillus spp. DNA, which is rich in unmethylated CpG motifs, was 
shown to activate TLR9, inducing a tolerogenic and anti-allergic immune response in the gut. 
Although not necessarily related to the anti-α-Gal immune response, recently Villarino et al.  
showed that the composition of the gut microbiota is a risk factor for severe malaria. They 
provided evidence that abundance increase of Lactobacillus and Bifidobacterium in the gut 
flora is associated with resistance to malaria in mice and proposed the modulation of the gut 
microbiota using probiotics as a potential intervention to reduce malaria severity. In the 
context of the increasing burden of emerging VBDs worldwide, we propose the use of 
probiotics composed of bacteria producing the carbohydrate α-Gal as dietary supplements to 
control VBDs. Although previous studies have shown that anti-α-Gal antibodies in human 
serum do not induce 100% killing of Plasmodium, the use of probiotics containing bacteria-
producing α-Gal may alter host natural response to this carbohydrate resulting in increased 
protection to parasite infection. Considering the results of previous studies, while probiotics 
such as Lactobacillus spp. may constitute the appropriate carrier of α-Gal in probiotic-based 
vaccines against vector-borne pathogens, the combination with TLR4 agonists may be needed 
to develop a potent and protective immune response against this carbohydrate. Future studies 
should focus on the characterization of the mechanisms involved in the immune response to 
α-Gal. This antibody response may be effective against different vector-borne pathogens that 
contain α-Gal on their surface.  
Therefore, the probiotics-based vaccines exploiting this major evolutionary adaptation may 
constitute an effective strategy to reduce the impact of VBDs on human health. Although the 
road to probiotic-based vaccines appears to be challenging, the rational design of vaccines 
exploiting the special immunity of human to α-Gal may be our best strategic move to win our 
battle against VBDs. 
 
This research was partially supported by the European Union Framework Programme 7 [ANTIGONE project number 
278976]. The authors have no other relevant affiliations or financial involvement with any organization or entity 
with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript 
apart from those disclosed 
 
